Hostname: page-component-586b7cd67f-g8jcs Total loading time: 0 Render date: 2024-11-30T21:48:03.009Z Has data issue: false hasContentIssue false
  • English
  • Français

Attributable Costs and Length of Stay of an Extended-Spectrum Beta-Lactamase-Producing Klebsiella pneumoniae Outbreak in a Neonatal Intensive Care Unit

Published online by Cambridge University Press:  02 January 2015

Patricia W. Stone ,
Archana Gupta ,
Maureen Loughrey ,
Phyllis Della-Latta ,
Jeannie Cimiotti ,
Elaine Larson ,
David Rubenstein  and
Lisa Saiman
Patricia W. Stone*
Affiliation:
School of Nursing, Columbia University, New York, New York
Archana Gupta
Affiliation:
Department of Pediatrics, Columbia University, New York, New York
Maureen Loughrey
Affiliation:
Children's Hospital of New York, New York-Presbyterian Medical Center, Columbia University, New York, New York
Phyllis Della-Latta
Affiliation:
Department of Pathology, Columbia University, New York, New York
Jeannie Cimiotti
Affiliation:
School of Nursing, Columbia University, New York, New York
Elaine Larson
Affiliation:
School of Nursing, Columbia University, New York, New York Department of Epidemiology, Columbia University, New York, New York
David Rubenstein
Affiliation:
Department of Pediatrics, Columbia University, New York, New York
Lisa Saiman
Affiliation:
Department of Pediatrics, Columbia University, New York, New York Department of Epidemiology, Columbia University, New York, New York
*
617 West 168th Street, New York, NY 10032
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives:

To determine the costs of the interventions aimed at controlling the 4-month outbreak and to determine the attributable length of stay (LOS) associated with infection and colonization with extended-spectrum beta-lactamase-producing Klebsiella pneumoniae.

Design:

A retrospective cost analysis was conducted from the hospital perspective. A micro-costing approach was employed. The LOS of four groups of hospitalized patients were compared with each other. National Perinatal Information Center criteria were used to stratify infants for severity of risk. The LOS of each group was compared with that of a national sample of similarly stratified infants.

Setting:

A level III-IV, 45-bed neonatal intensive care unit.

Patients:

Infant groups were infected (n = 8), colonized (n = 14), concurrent cohort (n = 54), and prior cohort (n = 486).

Results:

The cost of the outbreak totaled $341,751. The largest proportion of costs was related to healthcare worker time providing direct patient care (2,489 hours at a cost of $146,331). Infected and colonized neonates had longer LOS than either the concurrent cohort or the prior cohort (P < .001). Compared with the national sample, infected infants had a 48.5-day longer mean LOS (95% confidence interval [CI95], 1.7 to 95.2), whereas the prior cohort's mean LOS was 6 days shorter (CI95, -9.4 to -2.9).

Conclusions:

This study increases the understanding of the burden of these multidrug-resistant organisms. Further research is needed to estimate the societal costs of these infections and the cost-effectiveness of preventive interventions.

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 24 , Issue 8 , August 2003 , pp. 601 - 606
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2003

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Jarvis, WR. Selected aspects of the socioeconomic impact of nosocomial infections: morbidity, mortality, cost, and prevention. Infect Control Hosp Epidemiol 1996;17:552–557.CrossRefGoogle ScholarPubMed
2.Centers for Disease Control and Prevention. Monitoring hospital-acquired infections to promote patient safety: United States, 1990-1999. MMWR 2000;49:149–153.Google Scholar
3.Flaherty, JP, Weinstein, RA. Nosocomial infection caused by antibiotic-resistant organisms in the intensive-care unit. Infect Control Hosp Epidemiol 1996;17:236–248.CrossRefGoogle ScholarPubMed
4.Pillay, T, Pillay, DG, Adhikari, M, Sturm, AW. Piperacillin/tazobactam in the treatment of Klebsiella pneumoniae infections in neonates. Am J Perinatal 1998;15:47–51.Google Scholar
5.Gonzalez-Vertiz, A, Alcantar-Curiel, D, Cuauhtli, M, et al.Multiresistant extended-spectrum beta-lactamase-producing Klebsiella pneumoniae causing an outbreak of nosocomial bloodstream infection. Infect Control Hosp Epidemiol 2001;22:723–725.Google Scholar
6.Hart, CA. Klebsiella and neonates. J Hosp Infect 1993;23:83–86.CrossRefGoogle ScholarPubMed
7.Lin, H. Antibiotic resistance in bacteria: a current and future problem. Adv Exp Med Biol 1999;455:387–396.Google Scholar
8.Otman, J, Cavassin, ED, Perugini, ME, Vidotto, MC. An outbreak of extended-spectrum beta-lactamase-producing Klebsiella species in a neonatal intensive care unit in Brazil. Infect Control Hosp Epidemiol 2002;23:8–9.Google Scholar
9.Johnson, AP, Weinbren, MJ, Ayling-Smith, B, Du Bois, SK, Amyes, SG, George, RC. Outbreak of infection in two UK hospitals caused by a strain of Klebsiella pneumoniae resistant to cefotaxime and ceftazidime. J Hosp Infect 1992;20:97–103.CrossRefGoogle ScholarPubMed
10.Pena, C, Pujol, M, Ardanuy, C, et al.An outbreak of hospital-acquired Klebsiella pneumoniae bacteremia, including strains producing extended-spectrum beta-lactamase. J Hosp Infect 2001;47:53–59.Google Scholar
11.Rebuck, JA, Olsen, KM, Fey, PD, Langnas, AN, Rupp, ME. Characterization of an outbreak due to extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in a pediatric intensive care unit transplant population. Clin Infect Dis 2000;31:1368–1372.CrossRefGoogle Scholar
12.Royle, J, Halasz, S, Eagles, G, et al.Outbreak of extended spectrum beta lactamase producing Klebsiella pneumoniae in a neonatal unit. Arch Dis Child Fetal Neonatal Ed 1999;80:F64–F68.CrossRefGoogle Scholar
13.Gross, R, Morgan, AS, Kinky, DE, Weiner, M, Gibson, GA, Fishman, NO. Impact of a hospital-based antimicrobial management program on clinical and economic outcomes. Clin Infect Dis 2001;33:289–295.CrossRefGoogle ScholarPubMed
14.Goldmann, DA, Huskins, WC. Control of nosocomial antimicrobial-resistant bacteria: a strategic priority for hospitals worldwide. Clin Infect Dis 1997;24:S139–S145.CrossRefGoogle ScholarPubMed
15.Nathisuwan, S, Burgess, DS, Lewis, JS. Extended-spectrum beta-lactamases: epidemiology, detection, and treatment. Pharmacotherapy 2001;21:920–928.CrossRefGoogle ScholarPubMed
16.Saiman, L, Lerner, A, Saal, L, et al.Banning artificial nails from health care settings. Am J Infect Control 2002;30:252–254.CrossRefGoogle ScholarPubMed
17.Stone, PW, Larson, EL, Kawar, L. A systematic audit of economic evidence linking nosocomial infections and infection control interventions: 1990-2000. Am J Infect Control 2002;30:145–152.CrossRefGoogle ScholarPubMed
18.U.S. Department of Labor. Consumer Price Indices. Washington, DC: U.S. Department of Labor; 2001. Available at www.bls.gov/cpi. Accessed January 5, 2002.Google Scholar
19.Gupta, A, Gabriel, P, Todd, B, et al.An outbreak of extended spectrum beta-lactamase producing Klebsiella pneumoniae in a neonatal intensive care unit. Presented at the 12th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America; April 6-9, 2002; Salt Lake City, UT.Google Scholar
20.Gold, MR, Siegel, JE, Russell, LB, Weinstein, MC. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.CrossRefGoogle ScholarPubMed
21.Centers for Disease Control and Prevention. Assessing the effectiveness of disease and injury prevention programs: costs and consequences. MMWR Recomm Rep 1995;44(RR10):1–10.Google Scholar
22.Agreement Between The New York State Nurses Association & New York Presbyterian Hospital: January 1, 1999 - December 31, 2001. Latham, NY: New York Nurses Association; 2000.Google Scholar
23.U.S. Department of Labor, Bureau of Labor Statistics. Occupational Employment Statistics. Washington, DC: U.S. Department of Labor, Bureau of Labor Statistics; 2000. Available at www.bls.gov/oes. Accessed January 5, 2002.Google Scholar
24.Cardinale, V, Chi, JC, eds. Drug Topics Red Book. Montvale, NJ: Medical Economics; 1995.Google Scholar
25.Schwartz, RM, Gagnon, DE, Muri, JH, Zhao, QR, Kellogg, R. Administrative data for quality improvement. Pediatrics 1999;103(1 suppl E):291–301.Google Scholar
26.Paidos Health Management Services, Inc. What Paidos Does. Deerfield, IL: Paidos Health Management Services; 2000. Available at www.paidosonline.com/physiciansandnurses_whatpaidosdoes.asp. Accessed January 8, 2002.Google Scholar
27.Wenzel, RP. The Lowbury lecture: the economics of nosocomial infections. J Hosp Infect 1995;31:79–87.CrossRefGoogle ScholarPubMed
28.Astagneau, P, Fleury, L, Leroy, S, et al.Cost of antimicrobial treatment for nosocomial infections based on a French prevalence survey. J Hosp Infect 1999;42:303–312.Google Scholar
29.Schulgen, G, Kropec, A, Kappstein, I, Daschner, F, Schumacher, M. Estimation of extra hospital stay attributable to nosocomial infections: heterogeneity and timing of events. J Clin Epidemiol 2000;53:409–417.CrossRefGoogle ScholarPubMed
30.Dominguez, TE, Chalom, R, Costatino, AT Jr. The impact of adverse patient occurrences on hospital costs in the pediatric intensive care unit. Crit Care Med 2001;29:169–174.Google Scholar
31.Coello, R, Glenister, H, Fereres, J, et al.The cost of infection in surgical patients: a case-control study. J Hosp Infect 1993;25:239–250.Google Scholar
32.Spearing, NM, Jensen, A, McCall, BJ, Neill, AS, McCormack, JG. Direct costs associated with a nosocomial outbreak of Salmonella infection: an ounce of prevention is worth a pound of cure. Am J Infect Control 2000;28:54–57.Google Scholar
33.Saint, S, Veenstra, DL, Lipsky, BA, The clinical and economic consequences of nosocomial central venous catheter-related infection: are antimicrobial catheters useful? Infect Control Hosp Epidemiol 2000;21:375–380.Google Scholar
34.Digiovine, B, Chenoweth, C, Watts, C, Higgins, M. The attributable mortality and costs of primary nosocomial bloodstream infections in the intensive care unit. Am J Respir Crit Care Med 1999;160:976–981.CrossRefGoogle ScholarPubMed
35.Pittet, D, Tarara, D, Wenzel, RP. Nosocomial bloodstream infection in critically ill patients: excess length of stay, extra costs, and attributable mortality. JAMA 1994;271:1598–1601.CrossRefGoogle ScholarPubMed
36.Faoagali, JL, Darcy, D. Chickenpox outbreak among the staff of a large, urban adult hospital: costs of monitoring and control. Am J Infect Control 1995;23:247–250.CrossRefGoogle ScholarPubMed
37.The Brooklyn Antibiotic Resistance Task Force. The cost of antibiotic resistance: effect of resistance among Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa on length of hospital stay. Infect Control Hosp Epidemiol 2002;23:106–108.CrossRefGoogle Scholar
38.Stone, PW, Chapman, RH, Sandberg, EA, Liljas, B, Neumann, PJ. Measuring costs in cost-utility analyses: variations in the literature. Int J Technol Assess Health Care 2000;16:111–124.Google Scholar
39.Reilly, J, Twaddle, S, Mcintosh, J, Kean, L. An economic analysis of surgical wound infection. J Hosp Infect 2001;49:245–249.Google Scholar